Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine

Mark A. Brockman, Francis Mwimanzi, Yurou Sang, Kurtis Ng, Olga Agafitei, Siobhan Ennis, Hope Lapointe, Landon Young, Gisele Umviligihozo, Laura Burns, Chanson Brumme, Victor Leung, Julio S.G. Montaner, Daniel Holmes, Mari DeMarco, Janet Simons, Masa Niikura, Ralph Pantophlet, Marc G. Romney, Zabrina L. Brumme
doi: https://doi.org/10.1101/2021.03.17.21253773
Mark A. Brockman
1Faculty of Health Sciences, Simon Fraser University, Burnaby BC, Canada
2Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby BC, Canada
3British Columbia Centre for Excellence in HIV/AIDS, Vancouver BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mark_brockman@sfu.ca mromney@providencehealth.bc.ca zbrumme@sfu.ca
Francis Mwimanzi
1Faculty of Health Sciences, Simon Fraser University, Burnaby BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yurou Sang
1Faculty of Health Sciences, Simon Fraser University, Burnaby BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kurtis Ng
1Faculty of Health Sciences, Simon Fraser University, Burnaby BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga Agafitei
1Faculty of Health Sciences, Simon Fraser University, Burnaby BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siobhan Ennis
1Faculty of Health Sciences, Simon Fraser University, Burnaby BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hope Lapointe
3British Columbia Centre for Excellence in HIV/AIDS, Vancouver BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Landon Young
4Division of Medical Microbiology and Virology, St. Paul’s Hospital, Vancouver BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gisele Umviligihozo
1Faculty of Health Sciences, Simon Fraser University, Burnaby BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Burns
6Department of Pathology and Laboratory Medicine, St. Paul’s Hospital, Vancouver BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chanson Brumme
3British Columbia Centre for Excellence in HIV/AIDS, Vancouver BC, Canada
5Department of Medicine, University of British Columbia, Vancouver BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor Leung
4Division of Medical Microbiology and Virology, St. Paul’s Hospital, Vancouver BC, Canada
7Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julio S.G. Montaner
3British Columbia Centre for Excellence in HIV/AIDS, Vancouver BC, Canada
6Department of Pathology and Laboratory Medicine, St. Paul’s Hospital, Vancouver BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Holmes
6Department of Pathology and Laboratory Medicine, St. Paul’s Hospital, Vancouver BC, Canada
7Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mari DeMarco
6Department of Pathology and Laboratory Medicine, St. Paul’s Hospital, Vancouver BC, Canada
7Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janet Simons
6Department of Pathology and Laboratory Medicine, St. Paul’s Hospital, Vancouver BC, Canada
7Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masa Niikura
1Faculty of Health Sciences, Simon Fraser University, Burnaby BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph Pantophlet
1Faculty of Health Sciences, Simon Fraser University, Burnaby BC, Canada
2Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc G. Romney
4Division of Medical Microbiology and Virology, St. Paul’s Hospital, Vancouver BC, Canada
7Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mark_brockman@sfu.ca mromney@providencehealth.bc.ca zbrumme@sfu.ca
Zabrina L. Brumme
2Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby BC, Canada
3British Columbia Centre for Excellence in HIV/AIDS, Vancouver BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mark_brockman@sfu.ca mromney@providencehealth.bc.ca zbrumme@sfu.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Several Canadian provinces are extending the interval between COVID-19 vaccine doses to increase population vaccine coverage more rapidly. However, immunogenicity of these vaccines after one dose is incompletely characterized, particularly among the elderly, who are at greatest risk of severe COVID-19.

Methods We assessed SARS-CoV-2 humoral responses pre-vaccine and one month following the first dose of BNT162b2 mRNA vaccine, in 12 COVID-19 seronegative residents of long-term care facilities (median age, 82 years), 18 seronegative healthcare workers (HCW; median age, 36 years) and 4 convalescent HCW. Total antibody responses to SARS-CoV-2 nucleocapsid (N) and spike protein receptor binding domain (S/RBD) were assessed using commercial immunoassays. We quantified IgG and IgM responses to S/RBD and determined the ability of antibodies to block S/RBD binding to ACE2 receptor using ELISA. Neutralizing antibody activity was also assessed using pseudovirus and live SARS-CoV-2.

Results After one vaccine dose, binding antibodies against S/RBD were ∼4-fold lower in residents compared to HCW (p<0.001). Inhibition of ACE2 binding was 3-fold lower in residents compared to HCW (p=0.01) and pseudovirus neutralizing activity was 2-fold lower (p=0.003).While six (33%) seronegative HCW neutralized live SARS-CoV-2, only one (8%) resident did (p=0.19). In contrast, convalescent HCW displayed 7- to 20-fold higher levels of binding antibodies and substantial ability to neutralize live virus after one dose.

Interpretation Extending the interval between COVID-19 vaccine doses may pose a risk to the elderly due to lower vaccine immunogenicity in this group. We recommend that second doses not be delayed in elderly individuals.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the Public Health Agency of Canada through a COVID-19 Immunology Task Force COVID-19 "Hot Spots" Award (2021-HQ-000120 to MAB, ZLB, MGR), the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01AI134229 to RP), and the Canada Foundation for Innovation through Exceptional Opportunities Fund COVID-19 awards (project #40947 to MAB, MN, ZLB; project #41067 to RP). MAB holds a Canada Research Chair, Tier 2, in viral pathogenesis and immunity. ZLB holds a Scholar Award from the Michael Smith Foundation for Health Research.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the University of British Columbia/Providence Health Care and Simon Fraser University Research Ethics Boards (protocol H20-03906).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All study data is available to qualified investigators by request to the corresponding authors. A data transfer agreement may be required.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted March 24, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine
Mark A. Brockman, Francis Mwimanzi, Yurou Sang, Kurtis Ng, Olga Agafitei, Siobhan Ennis, Hope Lapointe, Landon Young, Gisele Umviligihozo, Laura Burns, Chanson Brumme, Victor Leung, Julio S.G. Montaner, Daniel Holmes, Mari DeMarco, Janet Simons, Masa Niikura, Ralph Pantophlet, Marc G. Romney, Zabrina L. Brumme
medRxiv 2021.03.17.21253773; doi: https://doi.org/10.1101/2021.03.17.21253773
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine
Mark A. Brockman, Francis Mwimanzi, Yurou Sang, Kurtis Ng, Olga Agafitei, Siobhan Ennis, Hope Lapointe, Landon Young, Gisele Umviligihozo, Laura Burns, Chanson Brumme, Victor Leung, Julio S.G. Montaner, Daniel Holmes, Mari DeMarco, Janet Simons, Masa Niikura, Ralph Pantophlet, Marc G. Romney, Zabrina L. Brumme
medRxiv 2021.03.17.21253773; doi: https://doi.org/10.1101/2021.03.17.21253773

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (940)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (418)
  • Epidemiology (8967)
  • Forensic Medicine (4)
  • Gastroenterology (417)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1320)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (211)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10764)
  • Intensive Care and Critical Care Medicine (570)
  • Medical Education (199)
  • Medical Ethics (52)
  • Nephrology (221)
  • Neurology (1815)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1891)
  • Public and Global Health (4107)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (361)
  • Respiratory Medicine (547)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (206)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)